methyl 2-methoxy-4-acetylphenoxyacetate | 63787-20-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: methyl 2-methoxy-4-acetylphenoxyacetate
• 英文别名: Methyl 2-(4-acetyl-2-methoxyphenoxy)acetate
• CAS: 63787-20-2
• 化学式: C₁₂H₁₄O₅
• mdl: MFCD09935968
• 分子量: 238.24
• InChiKey: SWIPLDKGBDZMBH-UHFFFAOYSA-N

物化性质

• 沸点：
  349.2±27.0 °C(Predicted)
• 密度：
  1.159±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  61.8
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  methyl 2-methoxy-4-acetylphenoxyacetate 在 对甲苯磺酸 、 间氯过氧苯甲酸 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 生成
  参考文献：
  名称：

  Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists

  摘要：

  Free fatty acid receptor 1 (FFA1) is a new potential drug target for the treatment of type 2 diabetes because of its role in amplifying glucose-stimulated insulin secretion in pancreatic β-cell. In the present studies, we identified phenoxyacetic acid derivative (18b) as a potent FFA1 agonist (EC50=62.3 nM) based on the structure of phenylpropanoic acid derivative 4p. Moreover, compound 18b could significantly improve oral glucose tolerance in ICR mice and dose-dependently reduced glucose levels in type 2 diabetic C57BL/6 mice without observation of hypoglycemic side effect. Additionally, compound 18b exhibited acceptable PK profiles. In summary, compound 18b with ideal PK profiles exhibited good activity in vitro and in vivo, and might be a promising drug candidate for the treatment of diabetes mellitus.

  DOI：

  10.1016/j.bmc.2014.11.016
• 作为产物：
  描述：

  邻甲氧基苯乙酸酯 在 aluminum (III) chloride 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 44.0h， 生成 methyl 2-methoxy-4-acetylphenoxyacetate
  参考文献：
  名称：

  Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists

  摘要：

  Free fatty acid receptor 1 (FFA1) is a new potential drug target for the treatment of type 2 diabetes because of its role in amplifying glucose-stimulated insulin secretion in pancreatic β-cell. In the present studies, we identified phenoxyacetic acid derivative (18b) as a potent FFA1 agonist (EC50=62.3 nM) based on the structure of phenylpropanoic acid derivative 4p. Moreover, compound 18b could significantly improve oral glucose tolerance in ICR mice and dose-dependently reduced glucose levels in type 2 diabetic C57BL/6 mice without observation of hypoglycemic side effect. Additionally, compound 18b exhibited acceptable PK profiles. In summary, compound 18b with ideal PK profiles exhibited good activity in vitro and in vivo, and might be a promising drug candidate for the treatment of diabetes mellitus.

  DOI：

  10.1016/j.bmc.2014.11.016

文献信息

• .alpha.-Amino ketone derivatives
  申请人：Imperial Chemical Industries Limited

  公开号：US04105790A1

  公开（公告）日：1978-08-08

  The invention concerns .alpha.-aminoacyl derivatives of phenyl-, phenoxy-, thiophenoxy- and phenylsulphinylalkanoic acids together with their amides, esters and pharmaceutically acceptable salts; processes for their preparation; and pharmaceutical compositions for therapeutic use in inhibiting the formation of thrombi and also in reducing the persistence of thrombi formed in the blood of warm blooded animals. Representative compounds of the invention are methyl 4-(aminoacetyl)phenoxyacetate, 4-(aminoacetyl)phenoxyacetic acid and methyl 4-(aminoacetyl)-thiophenoxyacetate, preferably as their hydrochlorides.

  该发明涉及苯基、苯氧基、硫代苯氧基和苯基磺基烷酸的α-氨基酰衍生物，以及它们的酰胺、酯和药用盐；它们的制备方法；以及用于在温血动物的血液中抑制血栓形成并减少已形成血栓持续存在的治疗用药物组合物。该发明的代表性化合物包括甲基4-(氨基乙酰)苯氧乙酸酯、4-(氨基乙酰)苯氧乙酸和甲基4-(氨基乙酰)-硫代苯氧乙酸酯，最好以它们的盐酸盐形式。
• US4105790A
  申请人：——

  公开号：US4105790A

  公开（公告）日：1978-08-08
• Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists
  作者：Xuekun Wang、Tianxiao Zhao、Baowei Yang、Zheng Li、Jian Cui、Yuxuan Dai、Qianqian Qiu、Hao Qiang、Wenlong Huang、Hai Qian

  DOI：10.1016/j.bmc.2014.11.016

  日期：2015.1

  Free fatty acid receptor 1 (FFA1) is a new potential drug target for the treatment of type 2 diabetes because of its role in amplifying glucose-stimulated insulin secretion in pancreatic β-cell. In the present studies, we identified phenoxyacetic acid derivative (18b) as a potent FFA1 agonist (EC50=62.3 nM) based on the structure of phenylpropanoic acid derivative 4p. Moreover, compound 18b could significantly improve oral glucose tolerance in ICR mice and dose-dependently reduced glucose levels in type 2 diabetic C57BL/6 mice without observation of hypoglycemic side effect. Additionally, compound 18b exhibited acceptable PK profiles. In summary, compound 18b with ideal PK profiles exhibited good activity in vitro and in vivo, and might be a promising drug candidate for the treatment of diabetes mellitus.